MedTrace Logo

Proenkephalin for Prediction of Contrast-Associated Kidney Events

NCT03989505 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2022-05-18

No results posted yet for this study

Summary

Currently, contrast-induced kidney injury cannot be diagnosed on the day of cardiac catheterization. Recently, proenkephalin (penKid) was introduced as a new glomerular filtration marker. The aim of this study is to investigate whether the change in penKid level allows for early detection of affected patients.

Conditions

Interventions

DIAGNOSTIC_TEST

blood-draw for biomarker analyses

Blood will be drawn at three time-points: immediately before catherization, 12-24 hours after catheterization and 4-8 weeks after discharge. Creatinine will be measured for endpoint definition, while the markers urea, CRP (C-reactive protein), NGAL (neutrophil gelatinase-associated lipocalin), KIM-1 (kidney injury marker-1), cystatin C, suPAR (soluble urokinase-type plasminogen activator receptor), and penKid will be measured as biomarkers of interest.

Sponsors & Collaborators

  • Dr. med. Mahir Karakas

    lead OTHER

Principal Investigators

  • Mahir Karakas, MD · University Heart Center Hamburg

  • Johannes F Geng, MD · University Heart Center Hamburg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2018-12-01
Completion
2021-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03989505 on ClinicalTrials.gov